The GLP-1 off-ramp problem: why leaving patients without support is criminal

You started taking a GLP-1 drug like Ozempic or Wegovy because you wanted to lose weight, and it worked. But now you're asking a different question: what happens when I stop?

It's the only question that matters. Because no one stays on these drugs forever.

The inconvenient truth about GLP-1s

GLP-1 drugs work. Let's be clear about that. They suppress appetite, slow digestion, and for many people, they reduce weight quickly. What prescribing doctors often don't mention upfront is threefold.

First, the costs keep rising. Most people need to increase their dose over time as their body adapts. What starts at £200 a month can easily double, becoming unsustainable financially or practically.

Second, a significant portion of what people lose is muscle. Research shows that up to 40% of weight lost on GLP-1s is lean muscle mass: the tissue that keeps you strong, mobile, and metabolically healthy as you age. Losing it makes future weight loss harder and weight regain faster.

Third, most people stop within two years. Whether it's side effects, cost, life circumstances, or the realisation that the expense is open-ended, around 70% of people come off GLP-1s within 12 to 24 months. When they do, the weight comes back fast. Studies show up to 70% of lost weight returns, and it returns as fat rather than the muscle that was lost.

The NHS gives you two years, then nothing

In the UK, NHS guidelines allow for roughly two years of GLP-1 support. After that, you're on your own: no metabolic guidance, no habit coaching, no plan for what comes next. Just a prescription that stops, and a body that's been suppressed rather than retrained.

This is where the system fails. Your metabolism didn't reset itself while you were on the drug. It was suppressed. And the moment that suppression lifts, your body picks up exactly where it left off: defending the weight it remembers, ramping up hunger, slowing energy expenditure.

Without support, rebound is inevitable. The system failed, not the person inside it.

Why coming off without a plan is criminal

Let's call it what it is: leaving people without an off-ramp is negligent.

You've just spent two years, and thousands of pounds, losing weight. You've dealt with nausea, fatigue, maybe digestive chaos. You've watched the number on the scale drop. And then the prescription ends.

Now what?

If you haven't learned how your metabolism works, how to manage glucose, how to build hunger-regulating habits, or how to protect muscle, you're set up to fail. The weight returns, but this time it's harder to lose. Your muscle mass is lower. Your metabolic rate is slower. And your confidence is shot. The outcome is harm.

What the off-ramp should look like

Your body already makes GLP-1. It's a natural hormone produced in your gut in response to food. The drugs flood your system with a synthetic version to override your appetite signals.

You can train your body to produce more GLP-1 naturally, through the right combination of food choices, meal timing, movement, and metabolic feedback. The problem is that no one teaches you how.

What people need is visibility into how their metabolism actually works: real-time data on glucose, hunger patterns, and energy use; coaching that responds to their specific biology rather than generic advice scraped from a textbook.

They need to see what a protein-rich breakfast does to their morning glucose curve. How a 15-minute walk after lunch changes their afternoon energy. How sleep affects next-day cravings. How their body responds to carbs at different times of day.

This kind of feedback rewires the relationship with food. You stop relying on external suppression and start building internal regulation.

The bridge that doesn't exist

The healthcare system treats GLP-1s as a complete weight-loss intervention. Metabolic rehabilitation is a different project, and the off-ramp doesn't exist. There's no transition plan, no scaffolding to help people learn the skills they'll need when the drug runs out.

It's the equivalent of teaching someone to drive by having them sit in a self-driving car for two years, then ejecting them onto the motorway and wishing them luck.

The technology exists to do this better. Continuous glucose monitors are available. AI can interpret patterns and give personalised guidance. Behavioural science knows how to build lasting habits. We're just not using any of it in the place where it matters most: the moment someone stops taking the drug.

A failure of imagination

The scandal is that we've accepted GLP-1 drugs as the entire solution, when they're clearly just the start of something that requires much more.

We've built a system that prioritises short-term weight loss over long-term metabolic health, one that medicates and intervenes but leaves people unequipped for what comes after.

And when the prescription stops and the weight returns, the blame lands on the patient for lacking willpower. The system walks away.

The problem is healthcare design.

Until that changes, what we're doing is pausing obesity. Treating it properly, in a way that looks after long-term patient health, is going to come back to the lifestyle interventions we've all been failing at for many years.